+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851646
  • Report
  • December 2018
  • Region: Global
  • 188 pages
  • Transparency Market Research
1 of 2

Hemophilia Treatment Drugs Market - Overview

Hemophilia treatment drugs are products that are administered into the patient’s body in order to replace the blood clotting factors that are missing in their blood so that the blood can clot properly.  This report analyzes the current and future prospects of the hemophilia treatment drugs market based on product type, disease indication, distribution channel, and region.  

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of hemophilia treatment drugs market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market value in terms of US$ Mn for product type, disease indication, distribution channel, and region for the period 2018 to 2026.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on product type, disease indication, distribution channel, and region. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the hemophilia treatment drugs market in the current and future scenario. The report also provides Porter’s five force analysis that studies five factors and their impact on the hemophilia treatment drugs market.

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors would help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on region, the market has been analyzed for major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The study also covers detailed country analysis in the respective regions for the hemophilia treatment drugs market.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire Plc., Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi.

Strategic collaboration agreements and new product development was the primary strategy adopted by major market players to bolster their position in the hemophilia treatment drugs market.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hemophilia Treatment Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Regulatory Scenario by Region/globally
5.2. Key Mergers & Acquisitions
5.3. Pipeline Analysis
5.4. Clinical Trial Analysis
5.5. Technological Advancements

6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
6.3.1. Plasma derived coagulation factor concentrates
6.3.1.1. Factor VIII
6.3.1.2. Factor IX
6.3.1.3. Others
6.3.2. Recombinant coagulation factor concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Others
6.3.3. Others
6.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Product Type

7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Hemophilia Treatment Drugs Market Value Forecast by Disease Indication, 2016-2026
7.3.1. Hemophilia A
7.3.2. Hemophilia B
7.3.3. Others
7.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication

8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel

9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Hemophilia Treatment Drugs Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Hemophilia Treatment Drugs Market Attractiveness, by Country/Region

10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
10.2.1. Plasma derived coagulation factor concentrates
10.2.1.1. Factor VIII
10.2.1.2. Factor IX
10.2.1.3. Others
10.2.2. Recombinant coagulation factor concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Others
10.2.3. Others
10.3. North America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
10.3.1. Hemophilia A
10.3.2. Hemophilia B
10.3.3. Others
10.4. North America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Hemophilia Treatment Drugs Market Value Forecast by Country, 2016-2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Hemophilia Treatment Drugs Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By Disease Indication
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Europe Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
11.2.1. Plasma derived coagulation factor concentrates
11.2.1.1. Factor VIII
11.2.1.2. Factor IX
11.2.1.3. Others
11.2.2. Recombinant coagulation factor concentrates
11.2.2.1. Factor VIII
11.2.2.2. Factor IX
11.2.2.3. Others
11.2.3. Others
11.3. Europe Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
11.3.1. Hemophilia A
11.3.2. Hemophilia B
11.3.3. Others
11.4. Europe Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Hemophilia Treatment Drugs Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Disease Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region

12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
12.2.1. Plasma derived coagulation factor concentrates
12.2.1.1. Factor VIII
12.2.1.2. Factor IX
12.2.1.3. Others
12.2.2. Recombinant coagulation factor concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Others
12.2.3. Others
12.3. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
12.3.1. Hemophilia A
12.3.2. Hemophilia B
12.3.3. Others
12.4. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Disease Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region

13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Latin America Hemophilia Treatment Drugs Market Value Forecast by Product Type, 2016-2026
13.2.1. Plasma derived coagulation factor concentrates
13.2.1.1. Factor VIII
13.2.1.2. Factor IX
13.2.1.3. Others
13.2.2. Recombinant coagulation factor concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Others
13.3. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
13.3.1. Hemophilia A
13.3.2. Hemophilia B
13.3.3. Others
13.4. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Disease Indication
13.6.3. By Distribution Channel
13.6.4. By Country

14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Product Type, 2016-2026
14.2.1. Plasma derived coagulation factor concentrates
14.2.1.1. Factor VIII
14.2.1.2. Factor IX
14.2.1.3. Others
14.2.2. Recombinant coagulation factor concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Others
14.2.3. Others
14.3. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Disease Indication, 2016-2026
14.3.1. Hemophilia A
14.3.2. Hemophilia B
14.3.3. Others
14.4. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Distribution Channel, 2016-2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Hemophilia Treatment Drugs Market Value Forecast, by Country/Sub-region, 2016-2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Disease Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1.Market Player - Competition Matrix (by Tier and Size of companies)
15.2.Market Share Analysis by Company (2017)
15.3. Company Profiles
15.3.1. Biotest AG.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Business Overview
15.3.1.3. Product Portfolio
15.3.1.4. Financial Overview
15.3.1.5. SWOT Analysis
15.3.1.6. Strategic overview
15.3.2. Bayer AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Business Overview
15.3.2.3. Product Portfolio
15.3.2.4. Financial Overview
15.3.2.5. SWOT Analysis
15.3.3. CSL Limited
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Business Overview
15.3.3.3. Product Portfolio
15.3.3.4. Financial Overview
15.3.3.5. SWOT Analysis
15.3.3.6. Strategic overview
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Business Overview
15.3.4.3. Product Portfolio
15.3.4.4. Financial Overview
15.3.4.5. SWOT Analysis
15.3.4.6. Strategic overview
15.3.5. Kedrion
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Business Overview
15.3.5.3. Product Portfolio
15.3.5.4. Financial Overview
15.3.5.5. SWOT Analysis
15.3.5.6. Strategic overview
15.3.6. Novo Nordisk A/S
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Business Overview
15.3.6.3. Product Portfolio
15.3.6.4. Financial Overview
15.3.6.5. SWOT Analysis
15.3.6.6. Strategic overview
15.3.7. Octapharma
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Business Overview
15.3.7.3. Product Portfolio
15.3.7.4. Financial Overview
15.3.7.5. SWOT Analysis
15.3.7.6. Strategic overview
15.3.8. Pfizer, Inc
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Business Overview
15.3.8.3. Product Portfolio
15.3.8.4. Financial Overview
15.3.8.5. SWOT Analysis
15.3.8.6. Strategic overview
15.3.9. Sanofi
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Business Overview
15.3.9.3. Product Portfolio
15.3.9.4. Financial Overview
15.3.9.5. SWOT Analysis
15.3.9.6. Strategic overview
15.3.10. Shire Plc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Business Overview
15.3.10.3. Product Portfolio
15.3.10.4. Financial Overview
15.3.10.5. SWOT Analysis
15.3.10.6. Strategic overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll